A benzazepine derived from norbelladine. It is found in galanthus and other amaryllidaceae. Hysingla Er is a cholinesterase inhibitor that has been used to reverse the muscular effects of gallamine triethiodide and tubocurarine, and has been studied as a treatment for Alzheimer’s disease and other central nervous system disorders.
Hysingla Er is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. It is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. An early pathophysiological feature of Alzheimer’s disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Hysingla Er is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Hysingla Er’s effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that Hysingla Er alters the course of the underlying dementing process.
LD50=75 mg/kg (rat)